相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis
Rachel B. Salit et al.
BONE MARROW TRANSPLANTATION (2020)
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Rory M. Shallis et al.
BLOOD REVIEWS (2020)
Myelofibrosis biology and contemporary management
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model
Juan-Carlos Hernandez-Boluda et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Survival following allogeneic transplant in patients with myelofibrosis
Krisstina Gowin et al.
BLOOD ADVANCES (2020)
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry
Yadanar Lwin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis
Jan P. Bewersdorf et al.
TRANSFUSION (2020)
How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT
Olaf Penack et al.
BLOOD ADVANCES (2020)
HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
Jae-Ho Yoon et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Comparison of DIPSS and MYSEC-PM for prediction of outcome in post-PV and ET myelofibrosis after allogeneic stem-cell transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Donal McLornan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation
Daniele Mannina et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis
Maria Queralt Salas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Kavita Raj et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
Roni Tamari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Grzegorz Helbig et al.
MEDICAL ONCOLOGY (2019)
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen
Haris Ali et al.
BLOOD ADVANCES (2019)
Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Sharifah Shahnaz Syed Abd Kadir et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
Ayalew Tefferi et al.
LEUKEMIA (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
Andrew T. Kuykendall et al.
ANNALS OF HEMATOLOGY (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Elsa Lestang et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Impact of molecular residual disease post allografting in myelofibrosis patients
C. Wolschke et al.
BONE MARROW TRANSPLANTATION (2017)
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Mohamed Shanavas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Myelofibrosis: to transplant or not to transplant?
Rebecca Devlin et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2015)
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis
S. Slot et al.
BONE MARROW TRANSPLANTATION (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning
M. Shanavas et al.
BONE MARROW TRANSPLANTATION (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
V. Panagiota et al.
LEUKEMIA (2014)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Allogeneic hematopoietic stem cell transplantation for infants with idiopathic myelofibrosis
Ayad Ahmed Hussein et al.
PEDIATRIC TRANSPLANTATION (2013)
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk
Ian Nivison-Smith et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Bart L. Scott et al.
BLOOD (2012)
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
Vikas Gupta et al.
BLOOD (2012)
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
J. Abelsson et al.
BONE MARROW TRANSPLANTATION (2012)
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis
Haefaa Alchalby et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis
Markus Ditschkowski et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis
W. Nagi et al.
LEUKEMIA RESEARCH (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby et al.
BLOOD (2010)
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Francesca Patriarca et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
Daniella M. B. Kerbauy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Stem cell transplantation for myelofibrosis: a report from two Canadian centers
A Daly et al.
BONE MARROW TRANSPLANTATION (2003)
Meta-analysis of observational studies in epidemiology - A proposal for reporting
DF Stroup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
分享论文
